The cytotoxic T Lymphocyte (CTL) response is recognized as perhaps the most relevant functional measure that reflects cell-mediated acquired immune defense against viral infections and cancer. The CTL responses can evaluate effective antigen presentation by tumors and is a key assessment in how well a drug candidate enhances CTL responses in eradicating or killing tumors. This assay utilizes our proprietary HLA-matched CTL and tumor cell lines and is run in a 96 well format.
The assay is run in a 96 well plate and can accommodate up to 40 doses of the drug candidate. Each dose is a well.
We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.